biostudies-literatureLin YHMinistry of Science and Technology1169-1181https://www.ebi.ac.uk/biostudies/studies/S-EPMC9807465biostudies-literatureUnknown30(2)<h4>Background</h4>To cure advanced hypopharyngeal squamous cell carcinoma (HPSCC), primary operation followed by adjuvant (chemo-)radiotherapy (OP-CRT) or definitive chemoradiation (CCRT) are the two primary options. This study aimed to compare the failure patterns and long-term survival outcomes of HPSCC patients treated with these two strategies. PATIENTS AND METHODS: From 2007 to 2015, 198 pathologically confirmed HPSCC patients receiving either OP-CRT or CCRT were retrospectively reviewed. Failure patterns and survival outcomes stratified by the 7th American Joint Committee on Cancer staging system and treatment modalities were compared.<h4>Results</h4>One hundred and eighty-nine patients (95.4%) were stage III/IV and 62 patients (31.3%) received OP-CRT. Median follow-up duration was Annals of surgical oncologyDistinct Failure Patterns in Hypopharyngeal Cancer Patients Receiving Surgery-Based Versus Radiation-Based Treatment.PMC9807465MOST 109-2314-B-006-096Huang CCYen CJHsiao JRLai YHJiang SSWu YHChang JSSu YCChang CCLin CLLin YHTsai STHsueh WTChen YSWu SYOu CYLee WTfalseDistinct Failure Patterns in Hypopharyngeal Cancer Patients Receiving Surgery-Based Versus Radiation-Based Treatment.<h4>Background</h4>To cure advanced hypopharyngeal squamous cell carcinoma (HPSCC), primary operation followed by adjuvant (chemo-)radiotherapy (OP-CRT) or definitive chemoradiation (CCRT) are the two primary options. This study aimed to compare the failure patterns and long-term survival outcomes of HPSCC patients treated with these two strategies. PATIENTS AND METHODS: From 2007 to 2015, 198 pathologically confirmed HPSCC patients receiving either OP-CRT or CCRT were retrospectively reviewed. Failure patterns and survival outcomes stratified by the 7th American Joint Committee on Cancer staging system and treatment modalities were compared.<h4>Results</h4>One hundred and eighty-nine patients (95.4%) were stage III/IV and 62 patients (31.3%) received OP-CRT. Median follow-up duration was 2023-01-01T00:00:00Z2023 Feb2025-04-05T12:09:47.301Z2024-11-13T01:34:02.696ZS-EPMC98074653633673310.1245/s10434-022-12744-1